Details

Autor(en) / Beteiligte

• Miao, Xiaoniu
• Luo, Yi
• Huang, Xi
• Lee, Suki M Y
• Yuan, Zhijun
• Tang, Yongzhou
• Chen, Liandi
• Wang, Chao
• Wu, Fan
• Xu, Yifeng
• Jiang, Wenchao
• Gao, Wei
• Song, Xuedong
• Yan, Yao
• Pang, Tuling
• Chen, Cheng
• Zou, Yuefeng
• Fu, Weihui
• Wan, Liping
• Gilbert-Jaramillo, Javier
• Knight, Michael
• Tan, Tiong Kit
• Rijal, Pramila
• Townsend, Alain
• Sun, Joanne
• Liu, Xiaolin
• James, William
• Tsun, Andy
• Xu, Yingda

Titel

A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy

Ist Teil von

• mAbs, 2020-01, Vol.12 (1), p.1804241-1804241

Ort / Verlag

United States: Taylor & Francis

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• In the absence of a proven effective vaccine preventing infection by SARS-CoV-2, or a proven drug to treat COVID-19, the positive results of passive immune therapy using convalescent serum provide a strong lead. We have developed a new class of tetravalent, biparatopic therapy, 89C8-ACE2. It combines the specificity of a monoclonal antibody (89C8) that recognizes the relatively conserved N-terminal domain of the viral Spike (S) glycoprotein, and the ectodomain of ACE2, which binds to the receptor-binding domain of S. This molecule shows exceptional performance , inhibiting the interaction of recombinant S1 to ACE2 and transduction of ACE2-overexpressing cells by S-pseudotyped lentivirus with IC50s substantially below 100 pM, and with potency approximately 100-fold greater than ACE2-Fc itself. Moreover, 89C8-ACE2 was able to neutralize authentic viral infection in a standard 96-h co-incubation assay at low nanomolar concentrations, making this class of molecule a promising lead for therapeutic applications.